chrX-101407714-T-A
Variant summary
Our verdict is Likely pathogenic. The variant received 8 ACMG points: 8P and 0B. PM1PM2PP2PP3PP5_Moderate
The NM_000169.3(GLA):c.190A>T(p.Ile64Phe) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★). Synonymous variant affecting the same amino acid position (i.e. I64I) has been classified as Likely benign.
Frequency
Consequence
NM_000169.3 missense
Scores
Clinical Significance
Conservation
Publications
Genome browser will be placed here
ACMG classification
Our verdict: Likely_pathogenic. The variant received 8 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| GLA | NM_000169.3 | c.190A>T | p.Ile64Phe | missense_variant | Exon 1 of 7 | ENST00000218516.4 | NP_000160.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 23
GnomAD4 exome Cov.: 31
GnomAD4 genome Cov.: 23
ClinVar
Submissions by phenotype
Fabry disease Pathogenic:2
GLA p.Ile64Phe (c.190A>T) is a missense variant that changes the amino acid at residue 64 from Isoleucine to Phenylalanine. This variant has been observed in at least one proband affected with Fabry disease (PMID:26415523). At least one functional study has demonstrated a substantial alteration in protein function relative to the wild-type (PMID:26415523). It is absent or not present at a significant frequency in gnomAD. In silico models agree that this variant is possibly or probably damaging. In conclusion, we classify GLA p.Ile64Phe (c.190A>T) as a likely pathogenic variant.
Migalastat response Other:1
Pharmacological Chaperone response: no
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at